In fact, as much as $125B is spent every year in the US in an attempt to tackle periodontitis – regarded an ‘osteoimmune’ condition similar to osteoarthritis and osteoporosis – and its own attendant complication: bone reduction. ‘Osteoinflammation produces larger osteoclasts [bone cells],’ clarifies Dr. Michael Glogauer, Professor in the Faculty of Dentistry's Matrix Dynamics research laboratory and a lead researcher of the analysis. These ‘superosteoclasts’ cause harm as they type on the bone surface, and, once attached, spit out enzymes that chew apart at the bone – and loosen the teeth in the process.ARX-01 is founded on the company’s proprietary NanoTab dosage form, which enables delivery of sufentanil by the noninvasive oral transmucosal route. ‘We opt for very painful surgery within an elderly patient population to showcase the efficacy and protection of Sublingual Sufentanil NanoTabs in treating acute post-operative discomfort,’ said Pamela Palmer, M.D., Ph.D., chief medical officer of AcelRx Pharmaceuticals. ‘The superior attributes of both the medication and the dosage form enabled these extremely encouraging Phase 2 outcomes.’ This multicenter, double-blind, randomized, placebo-controlled, dose-finding Phase 2 study evaluated the efficacy and safety of ARX-01 in individuals undergoing elective unilateral knee substitution surgery.